Zynyz 500 mg/20 mL (25 mg/mL) injection Images
Generic Name: retifanlimab
This medication has been identified as Zynyz 500 mg/20 mL (25 mg/mL) injection. It is supplied by Incyte Corporation.
Zynyz is used in the treatment of Merkel Cell Carcinoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Zynyz 500 mg/20 mL (25 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Zynyz
- Generic Name
- retifanlimab
- Strength
- 500 mg/20 mL (25 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Incyte Corporation
- National Drug Code (NDC)
- 50881-0006
More about Zynyz (retifanlimab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
